전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-2 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
AntibodyLimited DatastaleEli Lilly and CompanyPhase 1

IMC-1121B (Ramucirumab, Ramucirumab (IMC-1121B))

Colorectal Carcinoma · Colorectal Carcinoma

#ColorectalCarcinoma#Antibody#Phase1#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

Ramucirumab DP (Ramucirumab DP)

Carcinoma of Urinary Tract; Urethral Carcinoma · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#monoclonal-antibody#UrethralCarcinoma+1
Trials 1Status Active
CGTLimited DatastaleCNBG-Virogin Biotech (Shanghai)…Phase 2

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell, Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection, Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)))

Metastatic Gastric Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Recombinant Human Interleukin-2 and Rituximab (Recombinant Human Interleukin-2 and Rituximab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#monoclonal-antibody#OncolyticVirotherapy+1
Trials 1Status Active
CGTLimited DatastaleThe Affiliated Hospital of Xuzh…Phase 1

Recombinant oncolytic adenovirus injection solution of VT-101 (Recombinant oncolytic adenovirus injection solution of VT-101)

Non-muscle Invasive Bladder Cancer · Non-muscle Invasive Bladder Cancer

#Non-muscleInvasiveBladderCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleGuangzhou Virotech Pharmaceutic…Phase 1

Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib (Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib)

Advanced/Metastatic Hepatocellular Carcinoma · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleTianjin Medical University Canc…Phase 2

Regorafenib and tislelizumab (Regorafenib and tislelizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Tianjin
Trials 1Status Recruiting
AntibodyLimited DatastaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#monoclonal-antibody#Carcinoma+3
Trials 1Status Active
AntibodyLimited DatastaleWashington University School of…Phase 1

Relatilmab (Relatilmab)

Advanced Melanoma; Metastatic Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase1#monoclonal-antibody#MetastaticMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Relatlimab FDC + Nivolumab)

Metastatic Triple-negative Breast Cancer · Metastatic Triple-negative Breast Cancer

#MetastaticTriple-negativeBreastC#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Recruiting
AntibodyLimited DatastaleLoyola UniversityPhase 2

infliximab (Remicaide, Remicaide (infliximab))

Toxic Epidermal Necrolysis · Toxic Epidermal Necrolysis

#ToxicEpidermalNecrolysis#Antibody#Phase2#monoclonal-antibody#Loyola
Trials 1Status Discontinued
AntibodyLimited DatastaleTevaPreclinical

Reslizumab (Reslizumab)

Asthma · Asthma

#Asthma#Antibody#Preclinical#monoclonal-antibody#Teva
Trials 1Status Active
AntibodyLimited DatastaleUniversity of Alabama at Birmin…Phase 1

Retifanlimab, INCAGN02385, INCAGN02390 (Retifanlimab, INCAGN02385, INCAGN02390)

Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase1#monoclonal-antibody#Lymphoma+2
Trials 1Status Discontinued
AntibodyLimited DatastaleSWOG Cancer Research NetworkPreclinical

Rilotumumab (Rilotumumab)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#Antibody#Preclinical#monoclonal-antibody#StageIVSquamousCellLungCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleAmgenPhase 3

Romosozumab (Romosozumab)

Postmenopausal Osteoporosis · Postmenopausal Osteoporosis

#PostmenopausalOsteoporosis#Antibody#Phase3#monoclonal-antibody#Amgen
Trials 1Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

S1904 CD19 CAR-T (S1904 CD19 CAR-T)

B-ALL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleAmsterdam UMC, location VUmcPhase 2

pembrolizumab (Keytruda, SABR + pembrolizumab)

NSCLC, Stage I · NSCLC, Stage I

#NSCLCStageI#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Active
AntibodyLimited DatastaleSanofiPhase 2

Tusamitamab ravtansine (SAR408701, SAR408701 (Tusamitamab ravtansine))

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) · Non-squamous Non-small-cell Lung Cancer

#Non-squamousNon-small-cellLungCa#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Discontinued

83 / 103 pages

← PreviousNext →